EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells

Sabrina Fischer, Lisa Marie Weber, Bastian Stielow, Miriam Frech, Clara Simon, Merle Geller, Julie Könnecke, Florian Finkernagel, Ignasi Forné iD, Andrea Nist, Uta-Maria Bauer, Thorsten Stiewe und 2 weitere

Nucleic Acids Research · 2024

DOI: 10.1093/nar/gkae437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Sabrina Fischer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Tumor Research (IMT), Philipps University of Marburg, Marburg 35043, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Transcription Factor AP-1, Inflammation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German José Carreras Leukemia Foundation, Fritz Thyssen Foundation, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation and accumulation of immature myeloid cells in the bone marrow. Inflammation plays a crucial role in AML progression, but excessive activation of cell-intrinsic inflammatory pathways can also trigger cell death. IRF2BP2 is a chromatin regulator implicated in AML pathogenesis, although its precise role in this disease is not fully understood. In this study, we demonstrate that IRF2BP2 interacts with the AP-1 heterodimer ATF7/JDP2, which is involved in activating inflammatory pathways in AML cells. We show that IRF2BP2 is recruited by the ATF7/JDP2 dimer to chromatin and counteracts its gene-activating function. Loss of IRF2BP2 leads to overactivation of inflammatory pathways, resulting in strongly reduced proliferation. Our research indicates that a precise equilibrium between activating and repressive transcriptional mechanisms creates a pro-oncogenic inflammatory environment in AML cells. The ATF7/JDP2-IRF2BP2 regulatory axis is likely a key regulator of this process and may, therefore, represent a promising therapeutic vulnerability for AML. Thus, our study provides new insights into the molecular mechanisms underlying AML pathogenesis and identifies a potential therapeutic target for AML treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTranscription Factor AP-1InflammationHumansCell Line, TumorActivating Transcription FactorsChromatinCell ProliferationRepressor ProteinsHEK293 CellsGene Expression Regulation, LeukemicProtein MultimerizationTranscription FactorsDNA-Binding Proteins

Substanzen

IRF2BP2 protein, humanTranscription Factor AP-1ATF7 protein, humanJDP2 protein, humanActivating Transcription FactorsChromatinRepressor ProteinsTranscription FactorsDNA-Binding Proteins

Autor:innen und Institutionen

  • Institute of Molecular Biology and Tumor Research (IMT), Philipps University of Marburg, Marburg 35043, Germany.
  • Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg 35043, Germany.
  • Translational Oncology Group, Center for Tumor Biology and Immunology (ZTI), Philipps University of Marburg, Marburg 35043, Germany.
  • Protein Analysis Unit, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Martinsried 82152, Germany.
  • Genomics Core Facility, Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University of Marburg, Marburg 35043, Germany.

ORCID-Profile: Ignasi Forné, Robert Liefke

Förderung

  • German José Carreras Leukemia Foundation
  • Fritz Thyssen Foundation
  • German Research Foundation
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Fischer, S., Weber, L. M., Stielow, B., Frech, M., Simon, C., Geller, M., Könnecke, J., Finkernagel, F., Forné, I., Nist, A., Bauer, U. M., Stiewe, T., Neubauer, A., & Liefke, R. (2024). IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae437

Vancouver

Fischer S, Weber LM, Stielow B, Frech M, Simon C, Geller M, et al. IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae437

BibTeX
@article{Fischer2024,
  author = {Fischer, Sabrina and Weber, Lisa Marie and Stielow, Bastian and Frech, Miriam and Simon, Clara and Geller, Merle and Könnecke, Julie and Finkernagel, Florian and Forné, Ignasi and Nist, Andrea and Bauer, Uta-Maria and Stiewe, Thorsten and Neubauer, Andreas and Liefke, Robert},
  title = {IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells},
  journal = {Nucleic Acids Research},
  year = {2024},
  doi = {10.1093/nar/gkae437}
}
Kostenlos starten →